Document Detail


Update on the management of atrial fibrillation: anticoagulation and medical therapy.
MedLine Citation:
PMID:  21744157     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
2010 saw the introduction of dabigatran (Pradaxa; Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT), following US Food and Drug Administration approval, into daily clinical practice in the United States as an alternative to Coumadin (Bristol-Myers-Squibb, New York, NY) therapy. Dronedarone (Multaq; Sanofi-Aventis, Bridgewater, NJ), originally approved for use in the United States in 2009, has seen further widespread deployment in contemporary clinical practice. Intravenous vernakalant (Cardiome Pharm, Vancouver, B.C., Canada; Merck & Co., Whitehouse Station, NJ) is being considered for approval in the United States and may serve as an alternative to current agents for safe and efficacious acute conversion from atrial fibrillation. We focus primarily on new information concerning these and other antiarrhythmic drug and anticoagulation therapies. We provide brief updates of recently published articles along with our perspective on how they will likely alter clinical practice now and in the future.
Authors:
Shueh Hao Lim; Hugh Calkins; Sunil K Sinha
Related Documents :
6103437 - Oral contraceptives and thromboembolic disease: effects of lowering oestrogen content.
22915847 - Glutathione-mediated release of bodipy® from peg cofunctionalized gold nanoparticles.
3822267 - The triphasics: insights for effective clinical use.
6662007 - The fine-thread method: lacrimation test for measuring ocular side-effects of drugs in ...
22863637 - Letter: lichenoid eruption induced by etanercept.
18356637 - New drugs for chronic hepatitis b: a review.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Current cardiology reports     Volume:  13     ISSN:  1534-3170     ISO Abbreviation:  Curr Cardiol Rep     Publication Date:  2011 Oct 
Date Detail:
Created Date:  2011-08-30     Completed Date:  2012-01-09     Revised Date:  2013-06-03    
Medline Journal Info:
Nlm Unique ID:  100888969     Medline TA:  Curr Cardiol Rep     Country:  United States    
Other Details:
Languages:  eng     Pagination:  387-93     Citation Subset:  IM    
Affiliation:
Division of Cardiology, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Amiodarone / analogs & derivatives*,  therapeutic use
Anisoles / administration & dosage,  therapeutic use*
Anti-Arrhythmia Agents / therapeutic use*
Anticoagulants / therapeutic use*
Atrial Fibrillation / drug therapy*,  physiopathology
Benzimidazoles / therapeutic use*
Drug Approval
Evidence-Based Medicine
Factor Xa / antagonists & inhibitors
Female
Humans
Infusions, Intravenous
Male
Practice Guidelines as Topic
Pyridines / therapeutic use*
Pyrrolidines / administration & dosage,  therapeutic use*
Randomized Controlled Trials as Topic
United States
United States Food and Drug Administration
Chemical
Reg. No./Substance:
0/Anisoles; 0/Anti-Arrhythmia Agents; 0/Anticoagulants; 0/Benzimidazoles; 0/Pyridines; 0/Pyrrolidines; 1951-25-3/Amiodarone; 2E18WX195X/dabigatran etexilate; 9G468C8B13/vernakalant; EC 3.4.21.6/Factor Xa; JQZ1L091Y2/dronedarone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Catheter-based Ablation for Ventricular Arrhythmias.
Next Document:  Biodegradation of methyl parathion and p-nitrophenol by a newly isolated Agrobacterium sp. strain Yw...